Search clinical trials for: AZD6918

Total 94 results

AstraZeneca

Completed

A Phase II , Placebo-controlled Study to Assess Efficacy of 28 Day Oral AZD9668 in Patients With Cystic Fibrosis (INCA)

Cystic Fibrosis

Sweden, Russian Federation, United Kingdom, Poland, Denmark, Germany
AstraZeneca

Recruiting

A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of Subcutaneous AZD6912 in Healthy Participants

Rheumatoid Arthritis

United Kingdom, Canada
AstraZeneca
Parexel

Completed

A Study to Assess the Amount of Drug Levels in Blood and Safety of AZD5718 Formulations in Healthy Volunteers

Coronary Artery Disease (CAD)

United Kingdom
AstraZeneca
Parexel

Completed

Study to Assess Relative Bioavailability and Safety of AZD5718 in Healthy Volunteers

Chronic Kidney Disease

United Kingdom
AstraZeneca

Completed

Study to Assess the Metabolism, Excretion and Pharmacokinetics of [14C]AZD1981 in Healthy Male Volunteers (ADME)

Healthy
AstraZeneca

Completed

A Dose Range Finding Study to Evaluate the Efficacy and Safety of AZD9668 Administered Orally at Three Dose Levels to Patients With Chronic Obstructive Pulmonary Disease (COPD) on Treatment With Tiotropium

Chronic Obstructive Pulmonary Disease

Korea, Republic of, Poland, Germany, Philippines, Ukraine, Japan, United States, Australia, Canada, Slovakia, Taiwan, Russian Federation
AstraZeneca

Active, not recruiting

A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced Cancer

Advanced Solid Tumours

United States, France, Spain
AstraZeneca

Completed

14729-D9831C00002- 1 Month Biopsy Study (Biopsy)

Chronic Obstructive Pulmonary Disease

United Kingdom, Germany, Netherlands
AstraZeneca

Completed

One Month Dose Response Study of AZD1981 in Asthma Patients Uncontrolled on Inhaled Steroids (OLIVE)

Asthma

Poland, Argentina, Brazil, Costa Rica
AstraZeneca

Completed

Investigation of Efficacy, Safety and Tolerability of Once and Twice Daily Doses of AZD1981 in Asthmatic Patients (Sweapea)

Asthma Patients

United States, Mexico, Russian Federation, South Africa, Romania, Ukraine, Japan, Argentina, Slovakia, Brazil
AstraZeneca

Terminated

Single Ascending Dose Study With Healthy Male Volunteers and Type II Diabetic Patients

Type 2 Diabetes

Sweden
AstraZeneca
Quotient Sciences

Completed

Study Evaluating the Pharmacokinetic and Mass Balance of Single Dose [14C] AZD5718 in Volunteers

Cardiovascular Disease

United Kingdom
AstraZeneca
Parexel

Completed

A Study to Assess the Bioavailability of Different Formulations of AZD5718 and the Food Effect on the Selected Formulation of AZD5718 in Healthy Volunteers

Coronary Artery Disease

United Kingdom
Massachusetts General Hospital
AstraZeneca

Recruiting

AZD6738 for Patients With Progressive MDS or CMML

Leukemia | Myelodysplastic Syndrome

United States
AstraZeneca

Completed

AZD9668 Relative Bioavailability

Chronic Obstructive Pulmonary Disease

Germany
Royal Marsden NHS Foundation Trust
AstraZeneca; Cancer Research UK; RM/ICR Biomedical Research Centre

Active, not recruiting

Phase I Study to Assess Safety of AZD6738 Alone and in Combination With Radiotherapy in Patients With Solid Tumours (Patriot)

Solid Tumour Refractory to Conventional Treatment

United Kingdom
AstraZeneca

Completed

Study to Assess the Efficacy and Safety of AZD1981 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (Columbus)

Moderate to Severe COPD

Sweden, Bulgaria, Poland, Denmark, Slovakia
AstraZeneca

Completed

A Two Week Study to Assess the Tolerability of AZD9668 in Chronic Obstructive Pulmonary Disease (COPD) Patients

Chronic Obstructive Pulmonary Disease (COPD)

Germany
AstraZeneca

Completed

Tolerability/Safety and Efficacy of Inhaled AZD4818 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (TOP)

Chronic Obstructive Pulmonary Disease (COPD)

Sweden, Denmark, Finland, Netherlands, Norway
AstraZeneca

Completed

Single and Multiple Ascending Doses of AZD1981 in Japan (JSAD/JMAD)

Healthy

United Kingdom
AstraZeneca

Terminated

This Study Will Assess the Safety and Tolerability of AZD8418 After Single Increasing Oral Doses

Healthy

United States
Entasis Therapeutics

Completed

AZD0914 Phase 1 ADME Study in Healthy Volunteers

Healthy

United States
AstraZeneca

Completed

AZD9668 Relative Bioavailability

Chronic Obstructive Pulmonary Disease

Germany
AstraZeneca

Completed

Phase I, Exploratory, Single Centre, Single Oral Dose AZD9668 and Intravenous Microdose of [C14] AZD9668, Healthy Subject

Healthy

United Kingdom
AstraZeneca

Completed

A Drug-drug Interaction Study to Investigate the Effects of AZD1981 on the Metabolism and Pharmacodynamics of Oral Contraceptives

Oral Contraceptives

Sweden
National University Heart Centre, Singapore
AstraZeneca

Recruiting

PASSIvation of Vulnerable Plaque With AZD5718 in AcuTe Coronary syndromE (PASSIVATE)

Acute Coronary Syndrome

Australia, New Zealand, Singapore
AstraZeneca

Completed

AZD5718 Phase IIa Study to Evaluate Efficacy, Safety and Tolerability of Oral AZD5718 in Patients With Coronary Artery Disease (CAD). (FLAVOUR)

Coronary Artery Disease

Denmark, Finland, Sweden
AstraZeneca

Completed

A Phase II , Placebo-controlled Study to Assess Efficacy of 28 Day Oral AZD9668 in Patients With Bronchiectasis (NEPAL)

Bronchiectasis

United Kingdom, Canada
AstraZeneca

Completed

Effect on Structural Changes in Airways, Measured by MSCT, of Twice Daily 60mg AZD9668 for 12 Weeks in Chronic Obstructive Pulmonary Disease (COPD) Patients

Chronic Obstructive Pulmonary Disease (COPD)

Romania, Ukraine, Denmark, Netherlands, Canada
AstraZeneca

Completed

Safety, Tolerability and Pharmacokinetics of Inhaled Doses of AZD4818 in Healthy Japanese Male Volunteers

Healthy

Japan
AstraZeneca

Completed

A Bioavailability Study Comparing 3 Different AZD1981 Tablets

Healthy

Sweden
AstraZeneca
CLL Consortium

Completed

AZD6738 First Time in Patient Multiple Ascending Dose Study

B Cell Lymphomas | 11q-deleted Relapsed/Refractory Chronic Lymphocytic Leukaemia (CLL), | Prolymphocytic Leukaemia (PLL)

United States
AstraZeneca

Completed

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD5718 After Single and Multiple Ascending Dose Administration to Healthy Male Subjects

Cardiovascular Disease | Healthy Male Subjects

United Kingdom
AstraZeneca
Parexel

Terminated

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD6615 in Healthy Subjects

Dyslipidemia

United States
AstraZeneca

Completed

AZD1981 Bioavailability Study of Intravenous (IV) and Oral Formulations

Healthy | Postmenopausal | Surgically Sterile Women

Sweden
AstraZeneca

Withdrawn

A Drug-Drug Interaction Study Between AZD9668 and Warfarin to Study the Effect of AZD9668 on the Metabolism and Effect of Warfarin

Pharmacokinetics | Pharmacodynamics

Sweden
AstraZeneca

Completed

Single Oral Dose of 60 mg [14C]AZD9668 in Healthy Male Volunteers (ADME)

Healthy

United Kingdom
AstraZeneca

Completed

AZD6088 Single Ascending Dose Study

Healthy Volunteers

United Kingdom
Johns Hopkins University
AstraZeneca

Completed

Efficacy and Safety of Chemoattractant Receptor-homologous Molecule Expressed on T Helper Type 2 (CRTh2) Antagonist AZD1981 in Chronic Idiopathic Urticaria (CIU) Antihistamines

Chronic Idiopathic Urticaria

United States
AstraZeneca

Completed

Pharmacokinetics in Adolescents (PEAK)

Asthma

Sweden
National Institute of Allergy and Infectious Diseases...

Completed

A Study to Evaluate the Safety, Tolerability and Plasma PK of a Single Oral Dose of Zoliflodacin in Healthy Male and Female Volunteers

Gonorrhoea

United States
AstraZeneca

Completed

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD5718 After Single and Multiple Ascending Dose Administration to Healthy Japanese Men

Coronary Artery Disease

United States
Acerta Pharma BV

Active, not recruiting

A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia

United Kingdom, Poland
AstraZeneca

Completed

A Drug-Drug Interaction Study to Study the Effect of AZD1981 on Warfarin

Pharmakokinetic

Sweden
Seoul National University Hospital

Recruiting

AZD6738 Plus Durvalumab in Biliary Tract Cancer

Bile Duct Cancer | Chemotherapy Effect

Korea, Republic of
Se-Hoon Lee
AstraZeneca

Completed

Durvalumab(MEDI4736) and AZD6738 Combination Therapy in Relapsed Small Cell Lung Cancer Subjects (SUKSES-N4)

Small Cell Lung Cancer

Korea, Republic of
University of Nottingham

Completed

Investigating the Effects of Beta-Hydroxy-Beta-Methylbutyrate on Glucose Handling in Older and Younger Men.

Insulin Resistance | Age Problems

United Kingdom
AstraZeneca

Active, not recruiting

Phase II Umbrella Study of Novel Anti-cancer Agents in Patients With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy (HUDSON)

Non-Small Cell Lung Cancer

France, Spain, United States, Canada, Korea, Republic of, Austria, Israel, Germany
Mette M Berger
Texas A&M University

Completed

Can Beta-Hydroxy-beta-Methylbutyrate Supplementation Counteract Muscle Catabolism in Critically Ill Patients? (HMB-ICU-CH)

Critical Illness | Muscle Weakness

Switzerland
Samsung Medical Center

Active, not recruiting

This Study is a Phase II Study of AZD6738 in Combination With Durvalumab in Patients With Solid Tumor (Cohort A (N=30): GC Who Have Failed Secondary Chemotherapy Treatments Regimen; Cohort B (B=30): Melanoma Patients Who Have Failed to IO)

Gastric Adenocarcinoma | Malignant Melanoma

Korea, Republic of

3

Subscribe